Merck
U.S. pharma major behind Keytruda, the world's top-selling cancer immunotherapy.
Coverage of Merck is holding steady : 3 signals on the latest tracked day, down 57% from its three-week baseline of 7, across 2 domains (down from 3 a week ago). That makes it the #141 most-covered of the 274 concerns we track.
What’s changed
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch · BioPharma Dive — Latest News · 2026-08-06
- Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials · Reddit r/biotech · 2026-08-05
- Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination · Fierce Biotech · 2026-07-31
- Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’ · Fierce Biotech · 2026-08-06
- Merck Sales Roles · Reddit r/medicaldevices · 2026-08-06 · usually covers Medical Devices
- Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod · Fierce Pharma · 2026-08-01 · usually covers FDA Decisions
What the reporting says
Across 44 tracked stories from 16 outlets, reporting on Merck most often describes regulatory approvals (11), acquisition (3), IPOs or listings (1), launches or releases (1), public statements (1).
It shows up alongside Astrazeneca (15), Bristol Myers Squibb (13), FDA (16), Pfizer (14), Novartis (8), Eli Lilly (10), Immunotherapy (17), China (8).
Two steps out: Colorectal Cancer (through Immunotherapy, 17 shared stories on the weaker link); KRAS (through Immunotherapy, 17 shared stories on the weaker link); MSI-H (through Immunotherapy, 17 shared stories on the weaker link); AI (through FDA, 16 shared stories on the weaker link).
Tracked since May 5, with coverage on 22 separate days — concentrated in Preprint and Biotech Pharma.